Non-Hodgkin’s Lymphoma

P1, N=19, Recruiting, University Health Network, Toronto | Trial completion date: May 2026 --> Jun 2028 | Trial primary completion date: Mar 2026 --> Jun 2028

P2, N=76, Recruiting, University Health Network, Toronto | Trial completion date: Dec 2027 --> Dec 2029 | Trial primary completion date: Apr 2026 --> Apr 2029

P2, N=150, Recruiting, University Hospital, Clermont-Ferrand | Trial completion date: Dec 2027 --> May 2030 | Trial primary completion date: Oct 2026 --> May 2030

P1, N=12, Recruiting, University of Michigan Rogel Cancer Center | Not yet recruiting --> Recruiting

P3, N=737, Recruiting, Loxo Oncology, Inc. | Trial primary completion date: Jun 2025 --> Oct 2027

It highlights the diagnostic challenge of seronegative RPGN, in which MIDD should be included in the differential diagnosis. The case underscores the importance of integrated histopathology and hematologic genomics in identifying rare MGRS entities, recognizing that severe kidney injury may evolve rapidly despite appropriate management.

This case highlights the diagnostic complexity of composite indolent B-cell lymphomas and underscores the importance of integrated clinical, morphologic, immunophenotypic, and molecular assessment to inform management and surveillance.

Second, a network meta-analysis ranked the efficacy and safety of regimens including rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP); dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin plus rituximab (DA-EPOCH-R); R-CHOP plus lenalidomide (R2-CHOP); R-CHOP plus ibrutinib (I+R-CHOP); R-CHOP plus zanubrutinib (Z+R-CHOP); and R-CHOP plus venetoclax (Ven-R-CHOP). DEL is a distinct high-risk subtype with quantifiable prognostic detriment. Z+R-CHOP emerges as a promising strategy requiring validation in prospective studies.

Later, the patient received systemic chemotherapy with R-CHOP for eight cycles...This case presents unique features such as chronic abdominal pain and anorexia, which can lead to misdiagnosis due to a broad differential. There is a need to provide knowledge of primary colon lymphoma to ensure early diagnosis and favorable outcomes.

Prognostic nomograms incorporating these subtypes showed promising discriminative performance in internal validation (C-index > 0.78), but external validation is needed. Together, these findings identify a high-risk biological subset and provide a hypothesis-generating framework for future biomarker-driven risk stratification and therapeutic discovery in PCNSL.

In DLBCL MYD88 L265P mutation is found in 32% of cases and it is significantly more prevalent in cases with the non-GCB phenotype (OR 5.78 p value = 2.07 × 10⁻⁵) and in DLBCL of extranodal locations (OR = 5.44 p value p < 0.001), including, not only immuneprivileged sites but also the skin, breast, upper respiratory tract, adrenal gland and bone and soft tissues. MYD88L265P mutation is highly specific of the non-GCB type DLBCL, likely reflecting MCD/C5 genetic features in a subset of non-GCB/ABC DLBCL.